Login / Signup
Cardiovascular benefits of SGLT2 inhibition in diabetes and chronic kidney diseases.
Anita T Layton
V Vallon
Published in:
Acta physiologica (Oxford, England) (2018)
Keyphrases
</>
type diabetes
cardiovascular disease
glycemic control
insulin resistance
metabolic syndrome
drug induced
adipose tissue
skeletal muscle